Clinical Trial Update: A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the safety and tolerability of SAGE-718 in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment
• Dementia

Drugs mentioned

• SAGE-718

Snippet

Sponsor: Supernus Pharmaceuticals, Inc. | Conditions: Alzheimer Disease, Cognitive Dysfunction | Phase 2 | Status: COMPLETED | Results posted: 2024-10-10